H-CYTE Stock Price, News & Analysis (OTCMKTS:HCYTD) $2.02 -1.98 (-49.50%) (As of 07/11/2022) Add Compare Share Share Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/A About H-CYTE Stock (OTCMKTS:HCYTD)H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More HCYTD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCYTD Stock News HeadlinesNovember 2, 2023 | morningstar.comHyatt Hotels Corp Class A HJune 14, 2023 | forbes.comH-E-B Grocery CompanyDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 12, 2023 | marketwatch.com10-K: H-CYTE, INC.March 24, 2023 | seekingalpha.comHCYT H-CYTE, Inc.September 8, 2022 | finance.yahoo.comH-CYTE Completes Acquisition of JantibodyJuly 23, 2022 | apnews.comH-CYTE to Expect the Completed Acquisition of Jantibody Within 30 DaysJune 13, 2022 | finance.yahoo.comH-CYTE Announces 1-for-1,000 Reverse Stock SplitDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.March 6, 2022 | yahoo.comShould You Refrigerate Peanut Butter?March 6, 2022 | yahoo.comNetflix’s new superhero show might be the weirdest thing you ever watchMarch 4, 2022 | finance.yahoo.comH-CYTE Announces Proceeds of $1.05 Million from Warrant ExerciseFebruary 7, 2022 | nasdaq.comH-CYTE Inc (HCYT)January 11, 2022 | seekingalpha.comH-CYTE signs letter of intent to acquire Catheter PrecisionJanuary 11, 2022 | finance.yahoo.comH-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.December 6, 2021 | finance.yahoo.comH-CYTE Names Michael Yurkowsky Chief Executive OfficerSeptember 9, 2021 | au.finance.yahoo.comItalian court seeks opinion on Berlusconi's health due to trial delaysSeptember 8, 2021 | finance.yahoo.comH-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory HealthJuly 7, 2021 | ca.finance.yahoo.comJefferson Lines takes proactive steps toward crisis management with TSA I-STEP trainingJuly 7, 2021 | in.finance.yahoo.comScanfil plc: Managers' transactions – JokitaloJuly 6, 2021 | finance.yahoo.comH-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung HealthJuly 1, 2021 | in.finance.yahoo.comConstellium supplies advanced aluminium solutions for the electric Audi e-tron GTJuly 1, 2021 | au.finance.yahoo.comNetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon MagazineJune 29, 2021 | finance.yahoo.comH-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung HealthOctober 4, 2020 | msn.comNew Providence CEO: 'We have a responsibility and accountability to the community'September 29, 2020 | feeds.benzinga.comRobert Greif named Chief Executive Officer of H-CYTESeptember 27, 2020 | marketwatch.comThree Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QROSee More Headlines Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & Medical Instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HCYTD CUSIPN/A CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael W. Yurkowsky (Age 50)CEO & Director Comp: $180kMr. Jeremy Daniel (Age 46)Chief Financial Officer Comp: $200kDr. Tanya Rhodes Ph.D. (Age 61)Chief Scientific Officer Comp: $252kMr. Jeffery Wright CPA (Age 39)CPA, Controller & Principal Accounting Officer Key CompetitorsTodos MedicalOTCMKTS:TOMDFQuantRx BiomedicalOTCMKTS:QTXBPresbiaOTCMKTS:LENSFQHSLabOTCMKTS:USAQAssureNASDAQ:IONMView All Competitors HCYTD Stock Analysis - Frequently Asked Questions How have HCYTD shares performed in 2023? H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2023 here. How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:HCYTD) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.